🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCompounding & FormulationBeyond-use dating: 28 days vs 60 days — anyone have experience?

Beyond-use dating: 28 days vs 60 days — anyone have experience?

AussieAnna Thu, Apr 18, 2024 at 10:37 PM 7 replies 2,013 viewsPage 1 of 2
This thread is more than 26 months old. Information may be outdated. Consider searching for more recent discussions.
AussieAnna
Member
678
2,890
Jun 2024
Sydney, AU
Apr 18, 2024 at 10:37 PM#1

My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

The narrow version of the question is what actually distinguishes 503A from 503B, in terms of what each may make and from what starting material.

Numbers rather than impressions, if you have them.

50 3TrialNerd_Beth, HPLC_Greg, LibrarianMeg and 47 others
Reply Quote Save Share Report
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Apr 18, 2024 at 11:14 PM#2

Answering the narrow version, because the broad one does not have a single answer. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

Happy to go further on any of that.

Last edited: Apr 19, 2024 at 4:14 AM
1 4stefan_berlin
Reply Quote Save Share Report
tammy_FL
Member
234
890
Nov 2024
Tampa, FL
Apr 18, 2024 at 11:51 PM#3
TrialTracker_MD said:
The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

2 5kevin_tulsa, Dr.PainCLE
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
maria_elpaso
Member
312
1,456
Sep 2024
El Paso, TX
Apr 19, 2024 at 12:28 AM#4
AussieAnna said:
My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

Can confirm the pattern AussieAnna describes. They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

Last edited: Apr 19, 2024 at 6:28 AM
3 6HPLC_Greg, LibrarianMeg, bri_stats
Reply Quote Save Share Report
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
Apr 19, 2024 at 3:53 AM#5

Adding the clinical framing, because it changes how the question reads.

Compounding pharmacy licensing verification for compounded supply: before ordering, verify your pharmacy's credentials:

  1. State Board of Pharmacy license — check on your state BOP website
  2. FDA registration (for 503B) — check on fda.gov
  3. DEA registration if handling controlled substances
  4. PCAB accreditation — voluntary but demonstrates commitment to quality
  5. USP <797>/<800> compliance for sterile compounding

This takes 10 minutes of research and could save you from receiving substandard or unsafe medication.

4 7FranDenver, Dr.BariatricHTX, LindaRN_retired and 1 other
Reply Quote Save Share Report

Similar Threads

503A vs 503B compounding — regulatory framework explained4 replies
Compounded semaglutide stability: accelerated degradation study results6 replies
Lyophilized vs liquid peptides — stability and bioavailability comparison18 replies
Bacteriostatic water sourcing and sterility considerations8 replies
State-by-state compounding pharmacy regulations — 2026 map8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register